Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.50 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.50 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CPN1 | P15169 | 1/20 | 0.44 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | SLC6A1 | P30531 | 4/20 | 0.40 |
| ▸ | SLC6A11 | P48066 | 3/20 | 0.40 |
| ▸ | SLC6A13 | Q9NSD5 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3243645 | 1.00 | CHRNB2 (0.50) | CHRNB2CHRNB4CHRNA3CHRNA4KMT2A | |
| SCHEMBL3402477 | 1.00 | CHRNB2 (0.50) | CHRNB2CHRNB4CHRNA3CHRNA4KMT2A | |
| SCHEMBL17494202 | 0.89 | SLC6A1 (0.50) | CHRNB2CHRNB4CHRNA3CHRNA4KMT2A | |
| SCHEMBL28249888 | 0.89 | SLC6A1 (0.50) | CHRNB2CHRNB4CHRNA3CHRNA4KMT2A | |
| SCHEMBL28249924 | 0.89 | SLC6A1 (0.50) | CHRNB2CHRNB4CHRNA3CHRNA4KMT2A | |
| SCHEMBL27271782 | 0.82 | CHRNB2 (0.50) | CHRNB2CHRNB4CHRNA3CHRNA4KMT2A | |
| SCHEMBL27271788 | 0.82 | CHRNB2 (0.50) | CHRNB2CHRNB4CHRNA3CHRNA4KMT2A | |
| Hydrochloric Acid SCHEMBL28750161 | 0.81 | CHRNB2 (0.49) | CHRNB2CHRNB4CHRNA3CHRNA4KMT2A | |
| SCHEMBL23175088 | 0.81 | — | — | |
| SCHEMBL22751962 | 0.79 | CHRNB2 (0.48) | CHRNB2CHRNB4CHRNA3CHRNA4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119053590-A | Modulators of MYC family protooncogene proteins | 纳罗医疗公司 | 2024-11-29 | — | — | CN | disclosed |
| CN-117534665-A | Diacylglycerol kinase inhibitors | 山东轩竹医药科技有限公司 | 2024-02-09 | — | — | CN | disclosed |
| CN-117510497-A | DGK zeta inhibitors | 山东轩竹医药科技有限公司 | 2024-02-06 | — | — | CN | disclosed |
| CN-117412964-A | Substituted heterocyclic compounds and their use | 首药控股(北京)股份有限公司 | 2024-01-16 | — | — | CN | disclosed |
| CN-110267960-B | Substituted pyrazolo [1,5-a ] pyrazine compounds as RET kinase inhibitors | 阿雷生物药品公司 | 2022-04-26 | — | — | CN | disclosed |
| CN-113924292-A | Antimicrobial compounds and methods | 库扎环球有限责任公司 | 2022-01-11 | — | — | CN | disclosed |
| CN-113365996-A | Imidazopyridine derivative compounds and uses thereof | 韩美药品株式会社 | 2021-09-07 | — | — | CN | disclosed |
| US-20100184751-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | BALLELL-PAGES LLUIS | 2010-07-22 | — | — | US | disclosed |
| EP-2167196-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | Glaxo Group Limited (GB) | 2010-03-31 | — | — | EP | disclosed |
| WO-2009000745-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | GLAXO GROUP LIMITED (GB) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184751-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | SDHA, SDHB, NNT | CHRNB2 2856/4885CHRNB4 3098/4885CHRNA3 2686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.